| 4.75 -4.49 (-48.59%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.65 |
1-year : | 13.99 |
| Resists | First : | 9.12 |
Second : | 11.97 |
| Pivot price | 9.21 |
|||
| Supports | First : | 4.5 |
Second : | 3.74 |
| MAs | MA(5) : | 8.26 |
MA(20) : | 9.59 |
| MA(100) : | 9.2 |
MA(250) : | 9.41 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 25 |
D(3) : | 28  |
| RSI | RSI(14): 21.5 |
|||
| 52-week | High : | 13.64 | Low : | 4.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TPST ] has closed below the lower bollinger band by 36.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 123% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.26 - 9.31 | 9.31 - 9.35 |
| Low: | 4.44 - 4.47 | 4.47 - 4.5 |
| Close: | 4.7 - 4.75 | 4.75 - 4.79 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Wed, 19 Nov 2025
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - FinancialContent
Wed, 19 Nov 2025
Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld MedTech
Wed, 19 Nov 2025
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga
Wed, 19 Nov 2025
Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com
Wed, 05 Nov 2025
Tempest Therapeutics Reports Q3 2025 Financial Results - TipRanks
Wed, 05 Nov 2025
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 13.1 (%) |
| Shares Short | 156 (K) |
| Shares Short P.Month | 180 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.4 % |
| Return on Equity (ttm) | -405.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.49 |
| PEG Ratio | 0 |
| Price to Book value | 3.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|